Use open access data and collaborative methods to discover compounds that could lead to new medicines for mycetoma
current phase of drug development
updated 1 Mar 2022
The Mycetoma Open Source project (MycetOS) uses an ‘open source pharma’ approach to discover new treatments targeting M. mycetomatis, the predominant causative agent of fungal mycetoma (eumycetoma).
MycetOS was launched in 2018 by the University of Sydney, Australia, Erasmus MC (Erasmus University Medical Center, Rotterdam, the Netherlands), and DNDi.
MycetOS progresses drug discovery efforts through community-driven, in-kind scientific contributions and a robust, fully transparent online presence. All ideas and results are published immediately in real time to an open-access database, free of intellectual property constraints. Results and the associated data form the starting point for the MycetOS community, which communicates on Twitter (@MycetOS), uses a dedicated forum (subreddit) for transparent interactive discussion, and shares data and key project files on the GitHub platform.
Using this radically open approach, MycetOS aims to identify potential new treatments in a transparent and inclusive way.
News & resources
- 10 November 2021 – MycetOS: Harnessing the power of open source to develop treatments for a most neglected disease
- 9 May 2018 – Addressing the most neglected diseases through an open research model: the discovery of fenarimols as novel drug candidates for eumycetoma, PLOS Neglected Tropical Diseases
- 6 February 2018 – New open source drug discovery project aims to develop mycetoma treatment
- 1 January 2018 – MycetOS factsheet
- Dedicated subreddit forum for transparent, interactive discussion
- Data sharing and key project files will be shared on github
For further information, join the project communications on Twitter (@MycetOS).
Associate Professor Wendy van de Sande from Erasmus University, Rotterdam, Netherlands; Associate Professor Mat Todd at the University of Sydney, Australia; Ben Perry at DNDi.
Get our latest news, personal stories, research articles, and job opportunities.